Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection
Recruiting
Phase 1
Interventional Study
Hypertension
Hypertrophy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 19 – 75
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 112 (estimated)
- Sponsor
- Sunnybrook Health Sciences Centre · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The prevalence of congestive heart failure (CHF) in Canada is high, representing one of the health care system's most expensive diagnoses. Despite major advances in medicine, the mortality and morbidity from CHF remains great. Currently, magnetic resonance imaging (MRI) is used for non-invasive imaging of the cardiovascular system to enable the structure and anatomy of the organ to be visualized. …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
* Written consent
* Age: 19 to 50 in Arm 1, 30 to 75 in Arm 2
* Group 2A and 2E participants have left-ventricular hypertrophy
* Group 2B and 2F participants have diagnosed hypertrophic cardiomyopathy
* Group 2C and 2G participants are stable outpatients with NYHA class 1-3 heart…
Contacts